Who
Athena Countouriotis
Director
Company insider
Files Form 4 as: Director, Iovance Biotherapeutics; Director, BioMarin Pharmaceutical; Director, Passage Bio; President & CEO, Turning Point Therapeutics; Director, Cardiff Oncology; SVP, Chief Medical Officer, Adverum Biotechnologies; SVP and Chief Medical Officer, Halozyme Therapeutics; Chief Medical Officer, Ambit Biosciences.
In numbers
- Trades disclosed
- 96
- Buys
- 5
- Sells
- 4
- Bought
- $1.2M
- Sold
- $8.4M
- Companies
- 8
- Companies where not an officer
- 4
- First trade
- 16 Jul 2013
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,316 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,316 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,546 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —201,857 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,650 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,303 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —4,720 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —47,693 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 27 Dec 2023filed 28 Dec 2023 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —2,180 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,955 at $0.00 | filing |
| 25 May 2023filed 26 May 2023 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 17 Aug 2022filed 17 Aug 2022 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code D | —173,389 | filing |
| 17 Aug 2022filed 17 Aug 2022 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code D | —67,575 | filing |
| 17 Aug 2022filed 17 Aug 2022 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code D | —989,971 | filing |
| 17 Aug 2022filed 17 Aug 2022 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code D | —155,844 | filing |
News
No headline names them, or the companies they trade most, lately.